CN109568487A - 一种安神型辅助戒烟雾化吸入饮料及其制备方法 - Google Patents
一种安神型辅助戒烟雾化吸入饮料及其制备方法 Download PDFInfo
- Publication number
- CN109568487A CN109568487A CN201811548877.9A CN201811548877A CN109568487A CN 109568487 A CN109568487 A CN 109568487A CN 201811548877 A CN201811548877 A CN 201811548877A CN 109568487 A CN109568487 A CN 109568487A
- Authority
- CN
- China
- Prior art keywords
- extract
- water
- relative density
- extraction
- tranquilizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 230000005586 smoking cessation Effects 0.000 title claims abstract description 42
- 230000002936 tranquilizing effect Effects 0.000 title claims abstract description 33
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 64
- 239000002994 raw material Substances 0.000 claims abstract description 41
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 33
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 33
- 229940026510 theanine Drugs 0.000 claims abstract description 32
- 244000197580 Poria cocos Species 0.000 claims abstract description 30
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 30
- 210000000582 semen Anatomy 0.000 claims abstract description 21
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 18
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 18
- 235000008434 ginseng Nutrition 0.000 claims abstract description 18
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 15
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 15
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 15
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 15
- 239000004615 ingredient Substances 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims description 139
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 57
- 239000000341 volatile oil Substances 0.000 claims description 41
- 239000000047 product Substances 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 238000000605 extraction Methods 0.000 claims description 26
- 235000013409 condiments Nutrition 0.000 claims description 23
- 238000000265 homogenisation Methods 0.000 claims description 22
- 240000008866 Ziziphus nummularia Species 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 18
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 17
- 229940105902 mint extract Drugs 0.000 claims description 17
- 239000003995 emulsifying agent Substances 0.000 claims description 16
- 235000020710 ginseng extract Nutrition 0.000 claims description 14
- 238000012545 processing Methods 0.000 claims description 14
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 12
- 239000012467 final product Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 238000007689 inspection Methods 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 238000012859 sterile filling Methods 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 238000003860 storage Methods 0.000 claims description 8
- 238000003809 water extraction Methods 0.000 claims description 8
- 238000004945 emulsification Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 6
- 235000011194 food seasoning agent Nutrition 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 5
- 238000002137 ultrasound extraction Methods 0.000 claims description 5
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- 235000011449 Rosa Nutrition 0.000 claims description 2
- 238000003828 vacuum filtration Methods 0.000 claims 5
- 241000208340 Araliaceae Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 31
- 206010011224 Cough Diseases 0.000 abstract description 17
- 210000004072 lung Anatomy 0.000 abstract description 16
- 208000011580 syndromic disease Diseases 0.000 abstract description 15
- 210000002216 heart Anatomy 0.000 abstract description 12
- 208000019901 Anxiety disease Diseases 0.000 abstract description 11
- 210000000952 spleen Anatomy 0.000 abstract description 11
- 230000036506 anxiety Effects 0.000 abstract description 10
- 230000007958 sleep Effects 0.000 abstract description 9
- 238000000889 atomisation Methods 0.000 abstract description 7
- 230000001914 calming effect Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 206010036790 Productive cough Diseases 0.000 abstract description 6
- 208000006673 asthma Diseases 0.000 abstract description 5
- 239000002304 perfume Substances 0.000 abstract description 5
- 208000001431 Psychomotor Agitation Diseases 0.000 abstract description 4
- 206010038743 Restlessness Diseases 0.000 abstract description 4
- 230000009977 dual effect Effects 0.000 abstract description 2
- 235000013599 spices Nutrition 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 15
- 239000000796 flavoring agent Substances 0.000 description 14
- 235000019634 flavors Nutrition 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 13
- 229920000053 polysorbate 80 Polymers 0.000 description 13
- 230000000391 smoking effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 239000000470 constituent Substances 0.000 description 9
- 230000036541 health Effects 0.000 description 8
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 8
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 7
- 244000061176 Nicotiana tabacum Species 0.000 description 7
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229960002715 nicotine Drugs 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000013353 coffee beverage Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- -1 mint extract Substances 0.000 description 5
- 230000036651 mood Effects 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 4
- 235000017491 Bambusa tulda Nutrition 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 244000082204 Phyllostachys viridis Species 0.000 description 4
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 4
- 239000011425 bamboo Substances 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 3
- 241000237636 Pheretima Species 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- JJQWPDOBJQPJCS-UHFFFAOYSA-N Amlaic acid Natural products COC(=O)C1OC(=O)CC(C(O)=O)C1C1=C(O)C(O)=C(O)C=C1C(=O)OC1C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)OC(CO)CC1O JJQWPDOBJQPJCS-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 206010049976 Impatience Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000012287 Prolapse Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- KFDXRACNJCIDON-UHFFFAOYSA-N amlaic acid Chemical compound OC1C2OC(=O)C3=CC(O)=C(O)C(O)=C3C3C(C(O)=O)CC(=O)OC3C(=O)OC1C(CO)OC2OC(=O)C1=CC(O)=C(O)C(O)=C1 KFDXRACNJCIDON-UHFFFAOYSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- YRCWQPVGYLYSOX-UHFFFAOYSA-N synephrine Chemical compound CNCC(O)C1=CC=C(O)C=C1 YRCWQPVGYLYSOX-UHFFFAOYSA-N 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LRSHPKZSGRNHIX-UHFFFAOYSA-N 3, 6-di-O-galloyl-D-glucopyranoside Natural products OC1C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C(O)OC1COC(=O)C1=CC(O)=C(O)C(O)=C1 LRSHPKZSGRNHIX-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 244000274847 Betula papyrifera Species 0.000 description 1
- 235000009113 Betula papyrifera Nutrition 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 235000010928 Betula populifolia Nutrition 0.000 description 1
- 235000002992 Betula pubescens Nutrition 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000021479 Cardiovascular injury Diseases 0.000 description 1
- HGJXAVROWQLCTP-YABCKIEDSA-N Chebulagic acid Chemical compound O([C@H]1[C@H]2[C@H]3OC(=O)C4=CC(O)=C(O)C(O)=C4C4=C(O)C(O)=C(O)C=C4C(=O)OC[C@@H](O1)[C@H]3OC(=O)[C@@H](CC(O)=O)[C@@H]1[C@@H](C(OC=3C(O)=C(O)C=C(C1=3)C(=O)O2)=O)O)C(=O)C1=CC(O)=C(O)C(O)=C1 HGJXAVROWQLCTP-YABCKIEDSA-N 0.000 description 1
- 229920002052 Chebulagic acid Polymers 0.000 description 1
- 229920002361 Chebulic acid Polymers 0.000 description 1
- COZMWVAACFYLBI-UHFFFAOYSA-N Chebulic acid Natural products OC1=C(O)C(O)=C2C(C(CC(=O)O)C(O)=O)C(C(O)=O)OC(=O)C2=C1 COZMWVAACFYLBI-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- SXAMSIHRCZWLMU-UHFFFAOYSA-N Convallamarin Natural products CC1OC(OC2C(C)OC(OC3CC(CC4CCC5C(CCC6(C)C5CC7OC(O)(CCC(=C)COC8OC(CO)C(O)C(O)C8O)C(C)C67)C34C)OC9OC(CO)C(OC%10OC(C)C(O)C(O)C%10O)C(O)C9O)C(O)C2O)C(O)C(O)C1O SXAMSIHRCZWLMU-UHFFFAOYSA-N 0.000 description 1
- 229920002786 Corilagin Polymers 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- FTCAQUBXEGKQTD-UHFFFAOYSA-N D-8-Acetoxycarvotanacetone Natural products CC(=O)OC(C)(C)C1CC=C(C)C(=O)C1 FTCAQUBXEGKQTD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 241000222684 Grifola Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 235000013717 Houttuynia Nutrition 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- YFVGIJBUXMQFOF-SAXLCNSLSA-N Linarin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 YFVGIJBUXMQFOF-SAXLCNSLSA-N 0.000 description 1
- IJRBORPEVKCEQD-JMQWOFAPSA-N Makisterone A Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)C[C@@H](C)C(C)(C)O)CC[C@]33O)C)C3=CC(=O)[C@@H]21 IJRBORPEVKCEQD-JMQWOFAPSA-N 0.000 description 1
- YXPVYQIMXPYFSF-UHFFFAOYSA-N Makisterone A Natural products CC(C)C(C)(O)CC(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C YXPVYQIMXPYFSF-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- HMMCOAQTWLRBMU-WANIKOBHSA-N O1CC(C)CC[C@@]11C(=C)[C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CCCCC5CC[C@H]4[C@@H]3C[C@@H]2O1 Chemical compound O1CC(C)CC[C@@]11C(=C)[C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CCCCC5CC[C@H]4[C@@H]3C[C@@H]2O1 HMMCOAQTWLRBMU-WANIKOBHSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- PEFASEPMJYRQBW-HKWQTAEVSA-N Robinin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 PEFASEPMJYRQBW-HKWQTAEVSA-N 0.000 description 1
- 208000006227 SHORT syndrome Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 235000011517 Terminalia chebula Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 241000724115 Ziziphus lotus Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- MSUOLNSQHLHDAS-UHFFFAOYSA-N cerebronic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)C(O)=O MSUOLNSQHLHDAS-UHFFFAOYSA-N 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- UGIVASYMZSZAMP-UHFFFAOYSA-N chebulagic acid Natural products OC1C2c3c(OC1=O)c(O)c(O)cc3C(=O)OC4C(OC(=O)c5cc(O)c(O)c(O)c5)OC6COC(=O)c7cc(O)c(O)c(O)c7c8c(O)c(O)c(O)cc8C(=O)OC4C6OC(=O)C2(O)C(=O)O UGIVASYMZSZAMP-UHFFFAOYSA-N 0.000 description 1
- COZMWVAACFYLBI-XJEVXTIOSA-N chebulic acid Chemical compound OC1=C(O)C(O)=C2[C@H]([C@H](CC(=O)O)C(O)=O)[C@@H](C(O)=O)OC(=O)C2=C1 COZMWVAACFYLBI-XJEVXTIOSA-N 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- PSJVJZYSECBFHJ-BANYBNOTSA-N convallamarin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1C[C@@H](C[C@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@]21C)C)[C@@H]([C@@](O5)(O)CCC(=C)CO[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)C)O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](C)O1)O)[C@@H]1O[C@H](C)[C@H](O)[C@@H](O)[C@H]1O PSJVJZYSECBFHJ-BANYBNOTSA-N 0.000 description 1
- TUSDEZXZIZRFGC-XIGLUPEJSA-N corilagin Chemical compound O([C@H]1[C@H](O)[C@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@@H](O1)[C@H]2O)C(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-XIGLUPEJSA-N 0.000 description 1
- CPWYQGWOJMNXGJ-UHFFFAOYSA-N corilagin Natural products OC1C2COC(=O)c3c(O)c(O)c(O)c(O)c3c4c(O)c(O)c(O)c(O)c4C(=O)OC1C(O)C(OC(=O)c5cc(O)c(O)c(O)c5)O2 CPWYQGWOJMNXGJ-UHFFFAOYSA-N 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 239000009609 fructus phyllanthi Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- DDELFAUOHDSZJL-UHFFFAOYSA-N kaempferol 3-O-rutinoside-7-O-rhamnoside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C1=O DDELFAUOHDSZJL-UHFFFAOYSA-N 0.000 description 1
- PEFASEPMJYRQBW-UHFFFAOYSA-N kaempferol 7-O-alpha-L-rhamnopyradoside 3-O-beta-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(OC4C(C(O)C(O)C(C)O4)O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 PEFASEPMJYRQBW-UHFFFAOYSA-N 0.000 description 1
- 150000002561 ketenes Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 150000002729 menthone derivatives Chemical group 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229960003684 oxedrine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- PEFASEPMJYRQBW-XMWKPCQISA-N robinin Natural products O(C[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O4)c3)C2=O)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 PEFASEPMJYRQBW-XMWKPCQISA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- NUPTUAXNMUIMFS-MIHIQLSESA-N terchebin Chemical compound C([C@@H]1[C@H]2OC(=O)C=3[C@H]4C5=C(C(O[C@@H]([C@H](OC(=O)C=6C=C(O)C(O)=C(O)C=6)O1)[C@H]2OC(=O)C=1C=C(O)C(O)=C(O)C=1)=O)C=C(C(=C5OC4(O)C(O)(O)C(=O)C=3)O)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 NUPTUAXNMUIMFS-MIHIQLSESA-N 0.000 description 1
- ULYXEEKCDUUGNM-UHFFFAOYSA-N terchebin Natural products Oc1cc(cc(O)c1O)C(=O)OCC2OC(OC(=O)c3cc(O)c(O)c(O)c3)C4OC(=O)C5CC(=O)C(=O)C(=O)C5c6c(O)c(O)c(O)cc6C(=O)OC2C4OC(=O)c7cc(O)c(O)c(O)c7 ULYXEEKCDUUGNM-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 208000009189 tinea favosa Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种安神型辅助戒烟雾化吸入饮料及其制备方法。本发明饮料以安神定志、宁心除烦的酸枣仁为主要原料,佐以固本培元的人参、清热养阴的玉竹、滋阴益气的黄精,辅以肺燥平喘、祛风止咳、清热健脾的茯苓、陈皮、余甘子、薄荷,进一步添加国际公认安全有效的茶氨酸以引发和提高饮料的安神功能,多种有效成分共同作用缓解戒烟者咳嗽、痰多、焦虑、睡眠紊乱等戒烟不适综合征。同时,本发明饮料通过超声波雾化吸入的方式进行使用,可将产品药香与芳香调味成分相互融合,满足用户休闲与品香的双重需求。
Description
技术领域
本发明涉及一种安神型辅助戒烟雾化吸入饮料,属于保健饮品领域。
背景技术
吸烟对人体健康及公共环境危害极大。烟草中含有多种有害物质,吸烟时这些有害物质可进入人体,严重危害呼吸道、心血管、神经系统等组织器官,其中尤其焦油、尼古丁对人体的危害最为明显,焦油中含有多种致癌物质,吸入过多会发生肺癌、肺气肿等疾病,尼古丁含有毒素类物质,能刺激人体的神经系统,过量吸入会导致心血管损伤,引发呼吸道粘膜炎症,甚至诱发冠心病。此外,吸烟还会产生一氧化碳和pm2.5颗粒,对大气环境造成危害。而我国作为吸烟人口最多的国家,吸烟对于人民身体健康和公共环境的危害亟待解决。
近年来,吸烟人群基于对自身健康等因素的考量,戒烟情况日益增多,但大部分人在戒除烟瘾一段时间后又会不由自主的复吸,究其原因在于,烟草中的尼古丁是一种精神活性物质,且既是一种兴奋性生物碱,又具有抗焦虑作用,可以使人产生轻松愉快的感觉,长期吸入尼古丁,身体即习惯于血液中存在一定浓度的尼古丁,一旦血液中的尼古丁浓度下降,就会渴望恢复,进而出现戒烟不适综合症,具体表现为渴望吸烟或使用其他烟草制品、易激动、焦虑、难以集中注意力、心率下降、睡眠紊乱等。
为更好的帮助吸烟人群戒除烟瘾,现有技术中也存在多种辅助戒烟产品。例如CN201010184723公开了一种戒烟咖啡饮料,其由远志、地龙、鱼腥草、甘草、远志等中药材和咖啡调制组成;CN02133932公开了一种戒烟茶,其由由远志和地龙两味中药材组成。但现有的戒烟产品还存在不足之处,如CN201010184723的戒烟咖啡饮料,其由于咖啡成分的存在,其能刺激胃的腺体,促进胃酸及胃蛋白酶等消化液的分泌,从而造成胃部不适,并且,咖啡因作为一种中枢神经兴奋剂,小剂量使用能兴奋大脑皮层,加大剂量则有兴奋延髓呼吸及血管运动中枢的作用,对于暴躁、易怒、睡眠紊乱的戒烟者而言,使用添加咖啡因的产品不但不能起到缓解作用,反而会在一定程度上加重其戒烟不适综合症的症状。CN02133932的戒烟茶仅由远志和地龙组成,其味道咸、微辛、苦,其风味和口感不适宜作为日常饮品使用。此外,上述两款产品均是直接饮用,其不能直接作用于上呼吸道,对于有效成分的吸收和利用率较低。
发明内容
本发明为了解决上述技术问题,而提供一种安神型辅助戒烟雾化吸入饮料,其通过保健药材、功能原料的科学配比及超声雾化吸入的使用方式,不仅能够满足用户休闲和品香的需求,更能达到安神愉悦、舒缓戒烟不适综合征的功效。
为解决上述技术问题,本发明所采用的技术方案是:
一种安神型辅助戒烟雾化吸入饮料,主要成分为:酸枣仁提取物、人参提取物、玉竹提取物、黄精提取物、茯苓提取物、茶氨酸、陈皮提取物、余甘子提取物,薄荷提取物、水以及芳香调味辅料。
进一步的,主要成分用量(w%)为:酸枣仁提取物2~40%,人参提取物5~40%,玉竹提取物3~30%,黄精提取物3~30%,茯苓提取物3~30%,茶氨酸1~10%,陈皮提取物1~30%,余甘子提取物1~30%,薄荷提取物1-20%,调味辅料适量,水余量。
进一步的,主要成分用量(w%)为:酸枣仁提取物5~30%,人参提取物5~20%,玉竹提取物5~20%,黄精提取物5~20%,茯苓提取物3~15%,茶氨酸2~9%,陈皮提取物3~15%,余甘子提取物3~15%,薄荷提取物3-15%,调味辅料适量,水余量。
进一步的,主要成分用量(w%)为:酸枣仁提取物10-25%,人参提取物5-10%,玉竹提取物5-10%,黄精提取物5-10%,茯苓提取物3-8%,茶氨酸3-8%,陈皮提取物3-8%,余甘子提取物3-8%,薄荷提取物3-5%,调味辅料适量,水余量。
进一步的,调味辅料为精油以及乳化剂。
进一步的,乳化剂用量为1-5%(w%),精油用量为0.05-0.5%(w%),优选为乳化剂用量为3%(w%),精油用量为0.1%(w%)。
进一步的,乳化剂为吐温80、精油为天然植物香料提取精油。
进一步的,天然植物香料提取精油为柠檬精油、薄荷精油、玫瑰精油等。
进一步的,主要成分用量(w%)为:酸枣仁提取物20%,人参提取物10%,玉竹提取物10%,黄精提取物10%,茯苓提取物5%,茶氨酸5%,陈皮提取物5%,余甘子提取物5%,薄荷提取物4%,乳化剂3%,精油0.1%,水余量。
本发明还公开了一种安神型辅助戒烟雾化吸入饮料的制备方法,包括以下步骤:
(1)原料预处理:将酸枣仁、人参、玉竹、黄精、茯苓、陈皮、余甘子、薄荷分别清洗,沥干,粉碎处理;
(2)提取:步骤(1)中各原料分别采用水提醇沉法进行提取,提取液过滤后真空浓缩处理,制备相对密度为1.05-1.2的提取物;
(3)调味辅料预处理;
(4)调配、定容:将步骤(2)的各提取物与茶氨酸按照预定配比进行混合,加调味辅料调配,加水定容;
(5)均质:采用二次高压均质法均质处理,均质温度50-65℃,一次均质压力20-25MPa,二次均质压力25-30MPa;
(6)脱气:均质结束后冷却到室温,进行脱气处理;
(7)灭菌:30s/121℃高温杀菌,然后快速冷却至室温。
(8)无菌灌装、成品检验、包装、贮存。
进一步的,调味辅料预处理工艺为:采用吐温80将天然植物香料提取精油乳化处理。
进一步的,各原料提取工艺具体为:
酸枣仁提取物制备工艺:将酸枣仁原料加水提取2-3次,每次1-2小时,每次加水5-10倍水量,每次提取过程均采用微波辅助处理,温度50-70℃,微波功率400w,提取完毕后,混合提取液,真空浓缩提取液至相对密度为1.1-1.3,加无水乙醇至含醇量为70%-80%,静置12-18h,真空抽滤,滤液真空浓缩至相对密度为1.05-1.2即得。
人参、玉竹、黄精、茯苓提取物制备工艺同酸枣仁提取物制备工艺。
陈皮提取物制备工艺:将陈皮原料加水浸泡6-8h,常温超声辅助提取2-3次,每次1-2小时,每次加水5-10倍水量,超声频率40-50KHz,提取完毕后,混合提取液,真空浓缩提取液至相对密度为1.1-1.3,加无水乙醇至含醇量为70%-80%,静置12-18h,真空抽滤,滤液真空浓缩至相对密度为1.05-1.2即得。
余甘子、薄荷提取物制备工艺同陈皮提取物制备工艺。
本发明各成分作用如下:
酸枣仁,味甘、酸,性平,主要功能为养肝、宁心、安神、敛汗。酸枣仁能补养心肝之血而安神定志,最常用于肝胆血虚不能养心而致心烦不眠、多梦、易惊等症。酸枣仁甘酸而润,能敛虚汗,并能生津,偏用于肝胆虚热之证。酸枣仁活性成分主为酸枣仁苷,尚有白桦脂酸、黄酮类、阿魏酸、植物甾醇和大量的cAMP。有镇静、催眠;降血脂;抗衰老;保护缺氧心肌,抗惊厥、降温、镇痛等作用。
人参,味甘、微苦,性温、平。归脾、肺经、心经。补气,固脱,生津,安神,益智。用于气短喘促,心悸健忘,口渴多汗,食少无力,一切急慢性疾病及失血后引起的休克、虚脱。大补元气,固脱生津,安神。人参含有皂苷、多糖和挥发油等多种化学成分,人参皂苷为人参的主要有效成分之一,具有抗氧化、抗坏老、增强免疫等保健功效。
玉竹,味甘、微苦,性微寒。归肺、胃经。能善清肺热、养肺阴、益胃阴、生胃津.治肺胃阴虚有热诸证。玉竹中含有甾苷、维生素A、铃兰苦苷、铃兰苷、黏多糖等活性成分,能提高血清溶血素抗体水平,缓解动脉粥样斑块形成,扩张外周血管和冠状动脉,有降血脂、降血压、降血糖及强心作用,能改善患者燥咳、咽干口渴、阴虚外感、头昏眩晕等症状.并防治心血管病变。
黄精,味甘,性平。有养阴润肺、补脾益气、滋肾填精之功。主治阴虚劳嗽,肺燥咳嗽;脾虚乏力,食少口干,消渴;肾亏腰膝酸软,阳痿遗精,耳鸣目暗,须发早白,体虚赢瘦,风癞癣疾。黄精根状茎含2个呋甾烯醇型皂苷和2个螺甾烯醇型皂苷。另含多糖、低聚糖、氨基酸、黄酮、蒽醌等活性成分。药理研究表明,黄精具有抗病原微生物、降血脂、延缓衰老、提高免疫力、提高学习和记忆再现能力的作用,并能明显增加冠状动脉流量。
茯苓,味甘淡,性平,归心、肺、脾、肾经。具有利水渗是、健脾宁心功效,主要用于治疗水肿尿少,痰饮眩悸,脾虚食少,便溏泄泻,心神不安,惊悸失眠等病症。其主要化学成分为麦角甾醇,粗蛋白,25-去氧罗汉松甾酮A,α-羟基二十四酸,孔菌甾酮,甘露糖,半乳糖和猪苓多糖等。现代药理研究显示有利尿,促进免疫功能,抗癌,保肝和抗菌等作用,现代临床用于治疗急性肾炎水肿、慢性肾炎、急性肠炎腹泻、带下病、肺癌.慢性病毒性肝炎和银屑病等。
陈皮,味辛、苦,性温。归脾、肺经。功效理气健脾,燥湿化痰,降逆止呕。主治脾胃气滞,湿痰证,寒痰证,呕吐,呃逆等。陈皮主要含有挥发油、黄酮类、生物碱、肌醇等成分。挥发油中主要含右旋柠檬烯、β-月桂烯、γ-松油烯等;黄酮类主要为橙皮苷、新橙皮苷、柑橘素、川陈皮素.二氢川陈皮素、5-去甲二氢川陈皮素等;尚含有对羟福林、肌醇、维生素B1等。
余甘子,味甘、酸、涩,性凉。具有清热凉血、消食健胃、生津止咳的功效,可用于血热血瘀、消化不良、腹胀、咳嗽、喉痛、口干等症。余甘子鲜果中含有酚酸性成分、还原糖、多糖、黄酮、内酯、香豆素、甾醇、萜类和挥发油等。含丰富的氨基酸及蛋白质,其总蛋白质含量为苹果的3倍。干燥果实中含有黏酸,果皮含没食子酸、余甘子酸、胡萝卜素等。余甘子的鞣质含量较高,主要为葡萄糖没食子鞣质、没食子酸、并没食子酸、鞣云实精、原诃子素、诃子酸、诃黎勒酸、余甘子酸、余甘子酚、诃子裂酸及3,6-二没食子酰葡萄糖苷。还含有丰富的维生素B1、B2、C及微量元素K、Zn、Mn、Fe、Rb、Sr、Se等。
薄荷,味辛,性凉,归肺、肝经。具有疏散风热、清利头目、利咽、透疹、疏肝行气功效,用于风热感冒、风温初起、头痛、目赤、喉痹、口疮、风疹、麻疹、胸胁胀闷。主要含挥发油成分,油中主要成分为薄荷脑、薄荷酮、d-8-乙酰氧香芹艾菊酮、乙酸薄荷酯、甘菊环烃、薄荷烯酮、柠檬烯、莰烯等。其非挥发性成分有刺槐素、椴树素、蒙花苷、正丁基-β-D-吡喃果糖苷、熊果酸、齐墩果酸、β-谷甾醇和胡萝卜苷等。
茶氨酸,是茶叶中含有的一种特殊氨基酸,属于酰胺类化合物。其具有类似味精的鲜爽味,能够抑制其他食品的苦味和辣味,还具有抗肿瘤、抗糖尿病、降血、舒缓抑郁症、抗疲劳、保护心血管、醒酒、增强人体免疫力、保护神经、增强记忆等生理功能。
将以上具有多重保健功效的天然传统药食两用中药合用,具有宁心安神、补气养阴、润肺除燥等功效,其中以安神定志、宁心除烦的酸枣仁为君药,佐以大补元气、固本培元的人参、清热养阴的玉竹、滋阴益气的黄精,辅以茯苓、陈皮、余甘子、薄荷,提供肺燥平喘、祛风止咳、清热健脾之功效。诸药合奏,共同缓解戒烟者咳嗽痰多、易激动、焦虑、睡眠紊乱等戒烟不适综合征,尤其对于戒烟者烦躁、易激、抑郁等不良精神状态,能够起到较好的缓解功效。并且,为进一步增强产品的宁心除烦效果,创造性的配伍添加具有舒缓情绪、安神静心功效的茶氨酸,在使用过程中对戒烟者提供一定的镇静作用,从而抑制多巴胺、肾上腺素的分泌来控制机体神经递质水平,进而平复戒烟者对于尼古丁的渴望,从心理上缓解戒烟者焦躁的心情,从而使的戒烟人群更易于接受本发明产品,
本发明的有益效果是:
1、本发明的产品,具有宁心安神、补气养阴、润肺除燥等功效,首先从心理上舒缓戒烟人群焦虑的心里,为持续性的戒烟工作构建良好的心理基础,并且,通过补气养阴的药食两用原料对人体机能进行补充,为戒烟活动提供健康的生理基础,再者,采用润肺平喘、祛风止咳等解表药材,消除咳嗽、痰多等生理症状,从心理、生理等多方面针对戒烟综合征“对症下药”,取得良好的缓解功效。
2、本发明产品合理的选择具有舒缓情绪、安神静心功效的茶氨酸使用,在使用过程中对戒烟者提供一定的镇静作用,从而抑制多巴胺、肾上腺素的分泌来控制机体神经递质水平,进而平复戒烟者对于尼古丁的渴望,从心理上缓解戒烟者焦躁的心情,从而使的戒烟人群更易于接受本发明产品。
3、本发明中天然植物香料提取精油的使用,能够为产品提供芳香风味的同时,还能够提供一定的安神功效,舒缓戒烟综合征的不良症状。
4、本发明采用雾化吸入形式使用,相比于传统的饮用性饮品而言,其可以直接作用于上呼吸道,且其与上呼吸道作用时间延长,故此使用方式能够显著提高有效成分的吸收和利用率,同时显著的缩短起效时间。
5、本发明采用吐温80类乳化剂将精油乳化后添加使用,能够利于精油产品更好的与各保健原料提取物混合,并且,由于乳化剂的存在,可使得雾化后的小液滴可均匀的含有保健原料活性成分和精油成分,可使得雾化后的产品风味均一,保证良好的产品质量和使用舒适度,更利于消费者接受。
6、本发明的整个原料搭配及制备工艺合理,能很好地保留原料中的有效成分,不带入任何杂质,且口感芬芳,无毒副作用。
具体实施方式
下面将通过实施例对本发明作进一步的描述,这些描述并不是对本发明内容作进一步的限定。本领域的技术人员对发明内容所作的等同替换或改进,仍属于本发明的保护范围之内。
实施例1:
一种安神型辅助戒烟雾化吸入饮料,主要组成成分用量(w%)为:酸枣仁提取物10%,人参提取物5%,玉竹提取物5%,黄精提取物5%,茯苓提取物3%,茶氨酸3%,陈皮提取物3%,余甘子提取物3%,薄荷提取物3%,吐温80 1%,精油0.05%,水余量。
制备工艺包括以下步骤:
(1)原料预处理:将酸枣仁、人参、玉竹、黄精、茯苓、陈皮、余甘子、薄荷分别清洗,沥干,粉碎处理;
(2)提取:步骤(1)中各原料分别采用水提醇沉法进行提取,提取液过滤后真空浓缩处理,制备相对密度为1.2的提取物;
(3)调味辅料预处理:用吐温80将精油乳化处理以制备调味辅料;
(4)调配、定容:将步骤(2)的各提取物与茶氨酸按照预定配比进行混合,加调味辅料调配,加水定容;
(5)均质:采用二次高压均质法均质处理,均质温度50℃,一次均质压力20MPa,二次均质压力25MPa;
(6)脱气:均质结束后冷却到室温,进行脱气处理;
(7)灭菌:30s/121℃高温杀菌,然后快速冷却至室温。
(8)无菌灌装、成品检验、包装、贮存。
各原料提取工艺具体为:
酸枣仁提取物制备工艺:将酸枣仁原料加水提取2-3次,每次1-2小时,每次加水5-10倍水量,每次提取过程均采用微波辅助处理,温度50-70℃,微波功率400w,提取完毕后,混合提取液,真空浓缩提取液至相对密度为1.1-1.3,加无水乙醇至含醇量为70%-80%,静置12-18h,真空抽滤,滤液真空浓缩至相对密度为1.05-1.2即得。
人参、玉竹、黄精、茯苓提取物制备工艺同酸枣仁提取物制备工艺。
陈皮提取物制备工艺:将陈皮原料加水浸泡6-8h,常温超声辅助提取2-3次,每次1-2小时,每次加水5-10倍水量,超声频率40-50KHz,提取完毕后,混合提取液,真空浓缩提取液至相对密度为1.1-1.3,加无水乙醇至含醇量为70%-80%,静置12-18h,真空抽滤,滤液真空浓缩至相对密度为1.05-1.2即得。
余甘子、薄荷提取物制备工艺同陈皮提取物制备工艺。
实施例2:
一种安神型辅助戒烟雾化吸入饮料,主要组成成分用量(w%)为:酸枣仁提取物20%,人参提取物10%,玉竹提取物10%,黄精提取物10%,茯苓提取物5%,茶氨酸5%,陈皮提取物5%,余甘子提取物5%,薄荷提取物4%,吐温80 3%,精油0.1%,水余量。
制备工艺包括以下步骤:
(1)原料预处理:将酸枣仁、人参、玉竹、黄精、茯苓、陈皮、余甘子、薄荷分别清洗,沥干,粉碎处理;
(2)提取:步骤(1)中各原料分别采用水提醇沉法进行提取,提取液过滤后真空浓缩处理,制备相对密度为1.1的提取物;
(3)调味辅料预处理:用吐温80将精油乳化处理以制备调味辅料;
(4)调配、定容:将步骤(2)的各提取物与茶氨酸按照预定配比进行混合,加调味辅料调配,加水定容;
(5)均质:采用二次高压均质法均质处理,均质温度60℃,一次均质压力25MPa,二次均质压力30MPa;
(6)脱气:均质结束后冷却到室温,进行脱气处理;
(7)灭菌:30s/121℃高温杀菌,然后快速冷却至室温。
(8)无菌灌装、成品检验、包装、贮存。
各原料提取工艺同实施例1。
实施例3:
一种安神型辅助戒烟雾化吸入饮料,主要组成成分用量(w%)为:酸枣仁提取物25%,人参提取物8%,玉竹提取物8%,黄精提取物8%,茯苓提取物8%,茶氨酸8%,陈皮提取物8%,余甘子提取物8%,薄荷提取物5%,吐温80 5%,精油0.5%,水余量。
制备工艺包括以下步骤:
(1)原料预处理:将酸枣仁、人参、玉竹、黄精、茯苓、陈皮、余甘子、薄荷分别清洗,沥干,粉碎处理;
(2)提取:步骤(1)中各原料分别采用水提醇沉法进行提取,提取液过滤后真空浓缩处理,制备相对密度为1.05的提取物;
(3)调味辅料预处理:用吐温80将精油乳化处理以制备调味辅料;
(4)调配、定容:将步骤(2)的各提取物与茶氨酸按照预定配比进行混合,加调味辅料调配,加水定容;
(5)均质:采用二次高压均质法均质处理,均质温度65℃,一次均质压力20MPa,二次均质压力30MPa;
(6)脱气:均质结束后冷却到室温,进行脱气处理;
(7)灭菌:30s/121℃高温杀菌,然后快速冷却至室温。
(8)无菌灌装、成品检验、包装、贮存。
各原料提取工艺同实施例1。
对比例1:
一种安神型辅助戒烟雾化吸入饮料,主要组成成分用量(w%)为:茯苓提取物5%,茶氨酸5%,陈皮提取物5%,余甘子提取物5%,薄荷提取物4%,吐温80 3%,精油0.1%,水余量。
制备工艺包括以下步骤:
(1)原料预处理:将茯苓、陈皮、余甘子、薄荷分别清洗,沥干,粉碎处理;
(2)提取:步骤(1)中各原料分别采用水提醇沉法进行提取,提取液过滤后真空浓缩处理,制备相对密度为1.1的提取物;
(3)调味辅料预处理:用吐温80将精油乳化处理以制备调味辅料;
(4)调配、定容:将步骤(2)的各提取物与茶氨酸按照预定配比进行混合,加调味辅料调配,加水定容;
(5)均质:采用二次高压均质法均质处理,均质温度60℃,一次均质压力25MPa,二次均质压力30MPa;
(6)脱气:均质结束后冷却到室温,进行脱气处理;
(7)灭菌:30s/121℃高温杀菌,然后快速冷却至室温。
(8)无菌灌装、成品检验、包装、贮存。
各原料提取工艺同实施例1。
对比例2:
一种安神型辅助戒烟雾化吸入饮料,主要组成成分用量(w%)为:酸枣仁提取物20%,人参提取物10%,玉竹提取物10%,黄精提取物10%,茯苓提取物5%,陈皮提取物5%,余甘子提取物5%,薄荷提取物4%,吐温80 3%,精油0.1%,水余量。
制备工艺包括以下步骤:
(1)原料预处理:将酸枣仁、人参、玉竹、黄精、茯苓、陈皮、余甘子、薄荷分别清洗,沥干,粉碎处理;
(2)提取:步骤(1)中各原料分别采用水提醇沉法进行提取,提取液过滤后真空浓缩处理,制备相对密度为1.1的提取物;
(3)调味辅料预处理:用吐温80将精油乳化处理以制备调味辅料;
(4)调配、定容:将步骤(2)的各提取物按照预定配比进行混合,加调味辅料调配,加水定容;
(5)均质:采用二次高压均质法均质处理,均质温度60℃,一次均质压力25MPa,二次均质压力30MPa;
(6)脱气:均质结束后冷却到室温,进行脱气处理;
(7)灭菌:30s/121℃高温杀菌,然后快速冷却至室温。
(8)无菌灌装、成品检验、包装、贮存。
各原料提取工艺同实施例1。
对比例3:
一种安神型辅助戒烟雾化吸入饮料,主要组成成分用量(w%)为:酸枣仁提取物20%,人参提取物10%,玉竹提取物10%,黄精提取物10%,茯苓提取物5%,茶氨酸5%,陈皮提取物5%,余甘子提取物5%,薄荷提取物4%,精油0.1%,水余量。
制备工艺包括以下步骤:
(1)原料预处理:将酸枣仁、人参、玉竹、黄精、茯苓、陈皮、余甘子、薄荷分别清洗,沥干,粉碎处理;
(2)提取:步骤(1)中各原料分别采用水提醇沉法进行提取,提取液过滤后真空浓缩处理,制备相对密度为1.1的提取物;
(3)调配、定容:将步骤(2)的各提取物与茶氨酸按照预定配比进行混合,加精油调配,加水定容;
(4)均质:采用二次高压均质法均质处理,均质温度60℃,一次均质压力25MPa,二次均质压力30MPa;
(5)脱气:均质结束后冷却到室温,进行脱气处理;
(6)灭菌:30s/121℃高温杀菌,然后快速冷却至室温。
(7)无菌灌装、成品检验、包装、贮存。
各原料提取工艺同实施例1。
实施例4
感官评价:对实施例1-3及对比例1-3中制备的雾化吸入饮料进行感官评定试验,参与评价人员25人,对目标产品根据色泽、香气、口感、雾化状态进行相应的打分,其中雾化状态采用超声波电子烟雾化器形成,打分规则如下表(总分=0.2*a+0.2*b+0.2*c+0.4*d)。
感官试验结果如下:
色泽状态 | 香气 | 口感 | 雾化状态 | 合计 | |
实施例1 | 9.5 | 9.0 | 9.3 | 9.0 | 9.16 |
实施例2 | 9.6 | 9.4 | 9.5 | 9.5 | 9.50 |
实施例3 | 8.7 | 9.2 | 9.0 | 9.3 | 9.10 |
对比例1 | 9.0 | 8.6 | 8.7 | 8.8 | 8.78 |
对比例2 | 9.5 | 8.2 | 9.3 | 9.4 | 9.16 |
对比例3 | 8.0 | 8.3 | 8.2 | 7.0 | 7.70 |
本发明制备的雾化吸入饮料在感官评定方面表现优异,最高分为9.50,实施例1-3得分均超过9,说明本申请的雾化吸入饮料呈现出良好的色泽、风味、口感,在使用过程中也更便于形成均匀的雾化状态。相对于不添加酸枣仁、人参、玉竹、黄精的(对比例1)的雾化吸入饮料而言,本发明制备的雾化吸入饮料(尤其是实施例2的雾化吸入饮料)在色泽、香气、口感、雾化状态等多方面均呈现出较为较为明显的优势,说明,本申请的组方配比合理,制备的产品在感官和品质上更利于消费者使用;相对于不添加茶氨酸(对比例2)的雾化吸入饮料而言,本发明实施例2制备的雾化吸入饮料在口感方面呈现出较为较为明显的优势,进一步说明,茶氨酸的存在,能够抑制食品中其他的不良风味,对制备产品的风味、口感产生较为明显的改善;相对于不添加乳化剂(对比例3)的雾化吸入饮料而言,本发明制备的雾化吸入饮料(尤其是实施例2的雾化吸入饮料)在色泽、口感、雾化状态多方面呈现出较为较为明显的优势,说明,由于乳化剂的存在,能够利于精油类物质与其他原料的混合,从而为产品良好的色泽、口感提供帮助,同时,乳化剂也利于雾化液滴的成型和均一。
实施例5
保健功效
对实施例1-3及对比例1-3中制备的雾化吸入饮料进行辅助戒烟保健功效的测定。
试验人员:戒烟不适综合症人员50人(男40人、女10人,年龄25-35岁之间),主要症状为激动、焦虑、咳嗽、痰多、睡眠紊乱等。
试验方法:人员随机分为实验组5组,每组10人(男8人、女2人)。每日分早晚2次采用超声波电子烟雾化器各吸入待测样品20ml。5组人员吸入使用的待测样品分别为:实施例2产品(样品1),对比例1产品(样品2),对比例2产品(样品3),实施例2产品中乳化剂、精油、水的混合物(样品4),5%的茶氨酸水溶液(样品5)。使用2周后,对使用者感受进行调查问卷,
试验结果如下:
从试验结果可以看出,本发明制备的雾化吸入饮料对戒烟不适综合症人员的焦虑、咳嗽、痰多、睡眠紊乱等症状的改善明显,并显示出明显的镇静安神功效,对其中两项以上症状缓解的或改善的效果达到90%以上,说明本申请的雾化吸入饮料具有较为明显的减缓戒烟不适综合症的功效。相比于不添加酸枣仁、人参、黄精、玉竹的雾化吸入饮料(对比例1、样品2)而言,本发明的产品在镇静安神、缓解焦虑、改善睡眠紊乱方面效果明显,说明酸枣仁等主要保健成分在产品保健功效中起到极为重要的作用;相比于不添加茶氨酸的雾化吸入饮料(对比例2、样品3)而言,本发明的产品在缓解焦虑方面的效果明显,说明产品中的茶氨酸对于戒烟期间的情绪缓解焦虑具有重要作用;相对于仅添加茶氨酸的样品5而言,本发明的产品在镇静安神、润肺、止咳、平喘、改善睡眠紊乱等多个方面显示出明显的优势,并且,结合样品1、样品3、样品5进行综合比较,本申请的产品在缓解焦虑方面的效果明显优于样品3和样品5效果的总和,说明本申请的保健药材与茶氨酸酸的保健功效相互配合、相互补充,共同对戒烟不适综合症人员的不适症状起到预料不到的缓解功效。
本发明饮料以安神定志、宁心除烦的酸枣仁为主要原料,佐以大固本培元的人参、清热养阴的玉竹、滋阴益气的黄精,辅以肺燥平喘、祛风止咳、清热健脾的茯苓、陈皮、余甘子、薄荷,进一步添加国际公认安全有效的茶氨酸以引发和提高饮料的安神功能,多种有效成分共同作用缓解戒烟者咳嗽、痰多、焦虑、睡眠紊乱等戒烟不适综合征。同时,本发明饮料通过超声波雾化吸入的方式进行使用,可将产品药香与芳香调味成分相互融合,满足用户休闲与品香的双重需求。
应说明的是,以上实施例仅用以说明本发明的技术方案而非限制,尽管参照较佳实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的精神和范围,其均应涵盖在本发明的权利要求范围当中。
Claims (10)
1.一种安神型辅助戒烟雾化吸入饮料,其特征在于:主要成分用量(w%)为:酸枣仁提取物2~40%,人参提取物5~40%,玉竹提取物3~30%,黄精提取物3~30%,茯苓提取物3~30%,茶氨酸1~10%,陈皮提取物1~30%,余甘子提取物1~30%,薄荷提取物1-20%,调味辅料适量,水余量。
2.根据权利要求1所述的安神型辅助戒烟雾化吸入饮料,其特征在于:主要成分用量(w%)为:酸枣仁提取物10-25%,人参提取物5-10%,玉竹提取物5-10%,黄精提取物5-10%,茯苓提取物3-8%,茶氨酸3-8%,陈皮提取物3-8%,余甘子提取物3-8%,薄荷提取物3-5%,调味辅料适量,水余量。
3.根据权利要求1或2所述的安神型辅助戒烟雾化吸入饮料,其特征在于:所述调味辅料为精油以及乳化剂。
4.根据权利要求3所述的安神型辅助戒烟雾化吸入饮料,其特征在于:所述乳化剂为吐温80、精油为天然植物香料提取精油。
5.根据权利要求4所述的安神型辅助戒烟雾化吸入饮料,其特征在于:所述天然植物香料提取精油为柠檬精油、薄荷精油、玫瑰精油等可食用精油中的一种或多种。
6.根据权利要求3所述的安神型辅助戒烟雾化吸入饮料,其特征在于:所述乳化剂用量为1-5%(w%),精油用量为0.05-0.5%(w%),进一步优选乳化剂用量为3%(w%),精油用量为0.1%(w%)。
7.根据权利要求3-6任一项所述的安神型辅助戒烟雾化吸入饮料,其特征在于:主要成分用量(w%)为:酸枣仁提取物20%,人参提取物10%,玉竹提取物10%,黄精提取物10%,茯苓提取物5%,茶氨酸5%,陈皮提取物5%,余甘子提取物5%,薄荷提取物4%,乳化剂3%,精油0.1%,水余量。
8.一种安神型辅助戒烟雾化吸入饮料的制备方法,其特征在于:包括以下步骤:
(1)原料预处理:将酸枣仁、人参、玉竹、黄精、茯苓、陈皮、余甘子、薄荷分别清洗,沥干,粉碎处理;
(2)提取:步骤(1)中各原料分别采用水提醇沉法进行提取,提取液过滤后真空浓缩处理,制备相对密度为1.05-1.2的提取物;
(3)调味辅料预处理;
(4)调配、定容:将步骤(2)的各提取物与茶氨酸按照预定配比进行混合,加调味辅料调配,加水定容;
(5)均质:采用二次高压均质法均质处理,均质温度50-65℃,一次均质压力20-25MPa,二次均质压力25-30MPa;
(6)脱气:均质结束后冷却到室温,进行脱气处理;
(7)灭菌:30s/121℃高温杀菌,然后快速冷却至室温;
(8)无菌灌装、成品检验、包装、贮存;
其中,步骤(4)调配、定容过程中饮料各成分用量为权利要求3-7任一项所限定的成分用量。
9.根据权利要求8所述的安神型辅助戒烟雾化吸入饮料的制备方法,其特征在于:步骤(3)调味辅料预处理工艺为:采用乳化剂将精油乳化处理。
10.根据权利要求8或9所述的安神型辅助戒烟雾化吸入饮料的制备方法,其特征在于:
所述酸枣仁提取物制备工艺为:将酸枣仁原料加水提取2-3次,每次1-2小时,每次加水5-10倍水量,每次提取过程均采用微波辅助处理,温度50-70℃,微波功率400w,提取完毕后,混合提取液,真空浓缩提取液至相对密度为1.1-1.3,加无水乙醇至含醇量为70%-80%,静置12-18h,真空抽滤,滤液真空浓缩至相对密度为1.05-1.2即得;
所述人参提取物制备工艺为:将人参原料加水提取2-3次,每次1-2小时,每次加水5-10倍水量,每次提取过程均采用微波辅助处理,温度50-70℃,微波功率400w,提取完毕后,混合提取液,真空浓缩提取液至相对密度为1.1-1.3,加无水乙醇至含醇量为70%-80%,静置12-18h,真空抽滤,滤液真空浓缩至相对密度为1.05-1.2即得;
所述玉竹提取物制备工艺为:将玉竹原料加水提取2-3次,每次1-2小时,每次加水5-10倍水量,每次提取过程均采用微波辅助处理,温度50-70℃,微波功率400w,提取完毕后,混合提取液,真空浓缩提取液至相对密度为1.1-1.3,加无水乙醇至含醇量为70%-80%,静置12-18h,真空抽滤,滤液真空浓缩至相对密度为1.05-1.2即得;
所述黄精提取物制备工艺为:将黄精原料加水提取2-3次,每次1-2小时,每次加水5-10倍水量,每次提取过程均采用微波辅助处理,温度50-70℃,微波功率400w,提取完毕后,混合提取液,真空浓缩提取液至相对密度为1.1-1.3,加无水乙醇至含醇量为70%-80%,静置12-18h,真空抽滤,滤液真空浓缩至相对密度为1.05-1.2即得;
所述茯苓提取物制备工艺为:将茯苓原料加水提取2-3次,每次1-2小时,每次加水5-10倍水量,每次提取过程均采用微波辅助处理,温度50-70℃,微波功率400w,提取完毕后,混合提取液,真空浓缩提取液至相对密度为1.1-1.3,加无水乙醇至含醇量为70%-80%,静置12-18h,真空抽滤,滤液真空浓缩至相对密度为1.05-1.2即得;
所述陈皮提取物制备工艺:将陈皮原料加水浸泡6-8h,常温超声辅助提取2-3次,每次1-2小时,每次加水5-10倍水量,超声频率40-50KHz,提取完毕后,混合提取液,真空浓缩提取液至相对密度为1.1-1.3,加无水乙醇至含醇量为70%-80%,静置12-18h,真空抽滤,滤液真空浓缩至相对密度为1.05-1.2即得;
所述余甘子提取物制备工艺:将余甘子原料加水浸泡6-8h,常温超声辅助提取2-3次,每次1-2小时,每次加水5-10倍水量,超声频率40-50KHz,提取完毕后,混合提取液,真空浓缩提取液至相对密度为1.1-1.3,加无水乙醇至含醇量为70%-80%,静置12-18h,真空抽滤,滤液真空浓缩至相对密度为1.05-1.2即得;
所述薄荷提取物制备工艺:将薄荷原料加水浸泡6-8h,常温超声辅助提取2-3次,每次1-2小时,每次加水5-10倍水量,超声频率40-50KHz,提取完毕后,混合提取液,真空浓缩提取液至相对密度为1.1-1.3,加无水乙醇至含醇量为70%-80%,静置12-18h,真空抽滤,滤液真空浓缩至相对密度为1.05-1.2即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811548877.9A CN109568487A (zh) | 2018-12-18 | 2018-12-18 | 一种安神型辅助戒烟雾化吸入饮料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811548877.9A CN109568487A (zh) | 2018-12-18 | 2018-12-18 | 一种安神型辅助戒烟雾化吸入饮料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109568487A true CN109568487A (zh) | 2019-04-05 |
Family
ID=65929875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811548877.9A Pending CN109568487A (zh) | 2018-12-18 | 2018-12-18 | 一种安神型辅助戒烟雾化吸入饮料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109568487A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113350322A (zh) * | 2020-03-06 | 2021-09-07 | 李彤 | 一种多功能香薰液 |
CN113350557A (zh) * | 2020-03-06 | 2021-09-07 | 李彤 | 一种多用途香薰液 |
CN113768004A (zh) * | 2021-08-18 | 2021-12-10 | 福鼎市三余茶业有限公司 | 一种含陈皮的白茶调味茶及其制备方法 |
CN114948874A (zh) * | 2022-04-08 | 2022-08-30 | 四川农业大学 | 一种金丝楠润肺养肺雾化液及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104352589A (zh) * | 2014-10-09 | 2015-02-18 | 魏庆祥 | 一种以人参为主要原料的中药戒烟液及其制备方法 |
CN107970368A (zh) * | 2017-12-24 | 2018-05-01 | 谢小坚 | 一种帮助戒烟的鱼腥草口服液及其制备方法 |
CN108125013A (zh) * | 2018-02-06 | 2018-06-08 | 大连丹特生物技术有限公司 | 一种中药戒烟口香糖及其制备方法 |
-
2018
- 2018-12-18 CN CN201811548877.9A patent/CN109568487A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104352589A (zh) * | 2014-10-09 | 2015-02-18 | 魏庆祥 | 一种以人参为主要原料的中药戒烟液及其制备方法 |
CN107970368A (zh) * | 2017-12-24 | 2018-05-01 | 谢小坚 | 一种帮助戒烟的鱼腥草口服液及其制备方法 |
CN108125013A (zh) * | 2018-02-06 | 2018-06-08 | 大连丹特生物技术有限公司 | 一种中药戒烟口香糖及其制备方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113350322A (zh) * | 2020-03-06 | 2021-09-07 | 李彤 | 一种多功能香薰液 |
CN113350557A (zh) * | 2020-03-06 | 2021-09-07 | 李彤 | 一种多用途香薰液 |
CN113768004A (zh) * | 2021-08-18 | 2021-12-10 | 福鼎市三余茶业有限公司 | 一种含陈皮的白茶调味茶及其制备方法 |
CN114948874A (zh) * | 2022-04-08 | 2022-08-30 | 四川农业大学 | 一种金丝楠润肺养肺雾化液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109568487A (zh) | 一种安神型辅助戒烟雾化吸入饮料及其制备方法 | |
CN100393226C (zh) | 三参解烟排毒保健茶 | |
CN106035861A (zh) | 一种具有保健功能的桦褐孔菌代用茶及其制备方法 | |
CN109718330A (zh) | 一种提神型辅助戒烟雾化吸入饮料及其制备方法 | |
CN112314819A (zh) | 一种改善睡眠的植物饮料及其制备方法 | |
CN107853517B (zh) | 一种提神抗疲劳的中药饮料及其制备方法 | |
CN105920200A (zh) | 一种治疗血气不足的中药口服药液及制备方法 | |
CN105614719A (zh) | 一种美白祛斑的阿胶糕及其制备方法 | |
CN109364184A (zh) | 一种改善睡眠的保健型记忆枕 | |
KR20090002854A (ko) | 생약 발모제 조성물 및 이의 제조방법 | |
CN106912613A (zh) | 一种木瓜牛奶保健饮品及其制备方法 | |
CN107412345A (zh) | 一种百香果籽油含片及其制备方法 | |
TW202330006A (zh) | 氣虛及/或血虛相關症狀之預防、改善或緩和用之組合物 | |
CN108126160A (zh) | 中药组合物与中药养生茶及其制备方法与用途 | |
CN109123621A (zh) | 一种可调节机体免疫功能抑制血糖升高的保健食品 | |
CN108403933A (zh) | 一种月子餐下奶康复气血双补中药组合物及其制备方法 | |
CN106119040A (zh) | 一种铁皮石斛养生酒的制作工艺 | |
CN113632979A (zh) | 一种男女通用的四季养生饮料及其制备方法 | |
CN106135535A (zh) | 一种袋泡玫瑰芍药花茶及其制备方法 | |
CN105941716A (zh) | 一种解腻消食袋泡茶及其制备方法 | |
CN113018398A (zh) | 一种抗疲劳保健品及其制备方法 | |
CN112316066A (zh) | 一种含茉莉花的安神助眠中药配方红糖及其制备方法 | |
CN106072290A (zh) | 一种可减少孕吐又可补充营养的羹汤及制备方法 | |
KR20110101649A (ko) | 수면 유도용 조성물 | |
KR20160011461A (ko) | 기호성이 우수한 한방 혼합차 조성물 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190405 |